Literature DB >> 30401932

Benefit with VR-CAP in mantle cell lymphoma.

Diana Romero1.   

Abstract

Entities:  

Year:  2019        PMID： 30401932     DOI： 10.1038/s41571-018-0130-z

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.

Authors:  Tadeusz Robak; Jie Jin; Halyna Pylypenko; Gregor Verhoef; Noppadol Siritanaratkul; Johannes Drach; Markus Raderer; Jiri Mayer; Juliana Pereira; Gayane Tumyan; Rumiko Okamoto; Susumu Nakahara; Peter Hu; Carlos Appiani; Sepideh Nemat; Franco Cavalli
Journal:  Lancet Oncol       Date:  2018-10-19       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.